Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Spineway SA    ALSPW   FR0011398874

SPINEWAY SA

(ALSPW)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

SPINEWAY - 2019 : A year of restructuring - 2019 revenue of €5M

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/16/2020 | 12:00pm EST

 

SPINEWAY

2019: a year of restructuring
2019 revenue of €5M

2019 was a particularly active year for the SPINEWAY group as it redeployed its activities in previously covered areas, completely reorganized its teams and renewed half its Executive Committee at the end of 2019. Spineway also strengthened its financial position thanks to a financing agreement with Negma Group1 in order to ensure organic growth and finance new development projects. The Group thus generated total revenue of €5 015K for 2019.

 Annual revenue 2018 2019*
In thousands of euros 6 515 5 015

  * Unaudited figures

Increasing growth of the new Mont Blanc MIS product line
Sales of premium products represented a greater share of total revenue at 35% (compared with 29% in 2018), reflecting Spineway’s strength on this market segment. Although it is not yet distributed throughout all the Group’s territories, the Mont Blanc MIS (mini-invasive surgery) product line’s 2019 sales were up 8% (outside the USA). This premium product line, recently approved in Japan, has high growth potential.

Spineway continues its R&D work in order to provide new implants and instruments that will expand applications for its Mont Blanc MIS products line (trauma, deformity). Likewise, promotional and training activities were carried out for the Mont-Blanc 3D+ product line during the financial year and should bear fruit in the short and medium terms.

Economic downturn in Latin America but a positive outlook for 2020

Despite its uncertain geopolitical climate, Latin America remains the Group’s most dynamic area with revenue of €2.6M (compared with €3.4M in 2018). The 2019 financial year brought the consolidation of certain partnerships in Mexico following the strong mobilization of local teams (+14%) and in Brazil. Revenue should increase in these countries in 2020. Similarly, stabilization of the political situations in Peru and Chile should allow Spineway a return to growth in these countries where Spineway already has a history. In fact, Spineway’s regulatory affairs continue to be very active in this area as it is obtaining new registrations for its products so it can deploy the Mont-Blanc MIS product line throughout the continent.

Contrasting sales in Asia after a weak performance in China

Asia generated €705K in 2019 (compared with €1 283K including India in 2018) with improved customer loyalty in Southeast Asia and revenue in China of €145K compared with €506K in 2018. This drop in Chinese sales is due, in particular, to surplus inventory the previous year and delays in the granting of approvals for the Group’s products by the Chinese administrative authorities.
In Japan, following approval of its Mont-Blanc MIS product line, the Group is currently in advanced discussions with distributors for the importing of its products. These should soon result in the signature of a partnership agreement for the territory.

Solid activity in Europe and active prospecting in the United States

Revenue from Europe increased 13% to reach €1 158K, its highest in the Group’s history. This was achieved thanks to increased sales in France (+10%),as well as in Northern Europe.

The Middle-Est/Africa region generated €412K this year with efforts essentially focused on the Mont Blanc products.

Sales in the United States amounted to €148K, now only representing 3% of the 2019 revenue. Spineway suffered from the bankruptcy of its main distributor in 2018, the reorganization initiated by the new CEO and the referencing of products. The Group obtained a patent for the Mont-Blanc MIS product line, used for a technique that is increasingly being favored by spinal surgeons, and the US teams pursued their promotional efforts vis-à-vis US distributors and surgeons. Spineway, which invested in and undertook prospecting activities in 2019, should gradually return to growth on this high-potential territory.

Spineway continues to have a solid base for its activity in its existing territories and should be expediting the implementation of its new strategic plan in 2020 with, in particular, a new sales policy.

Next communication: 2019 annual results – 28 April 2020

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at www.spineway.com

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015). 
ISIN: FR0011398874 - ALSPW

Contacts:





Spineway

Ligne aux actionnaires
Ouverte du mardi au jeudi (10h-12h)
0811 045 555

 
Eligible PEA / PME

ALSPW

Euronext

Growth
Aelium

Relations investisseurs
Solène Kennis
spineway@aelium.fr

 




[1] See press release dated 18 October 2019

 

 

Attachment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SPINEWAY SA
01/16SPINEWAY - 2019 : A year of restructuring - 2019 revenue of €5M
GL
01/16SPINEWAY SA : 4th quarter earnings
CO
2019SPINEWAY : ERRATUM - First subscription phase in linked with NEGMA GROUP's agree..
GL
2019SPINEWAY : First subscription phase pursuant to the agreement for the issue of t..
PU
2019SPINEWAY : First subscription phase in linked with NEGMA GROUP's agreement
AQ
2019SPINEWAY : First subscription phase in linked with NEGMA GROUP's agreement
GL
2019SPINEWAY : Patent issued in Europe for the Mont-Blanc MIS range
PU
2019SPINEWAY : Patent issued in Europe for the Mont-Blanc MIS range
AQ
2019SPINEWAY : Patent issued in the USA for the Mont-Blanc MIS range
AQ
2019SPINEWAY : Approval of Mont-Blanc MIS in Japan
GL
More news
Financials (EUR)
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -1,00x
P/E ratio 2020 -
Capi. / Sales2019 -
Capi. / Sales2020 -
Capitalization 3,05 M
Chart SPINEWAY SA
Duration : Period :
Spineway SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPINEWAY SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 0,01  €
Last Close Price 0,01  €
Spread / Highest target 38,4%
Spread / Average Target 38,4%
Spread / Lowest Target 38,4%
EPS Revisions
Managers
NameTitle
Stéphane Le Roux Chairman & Chief Executive Officer
David Siegrist Chief Financial Officer
Joseph Brigneaud Independent Director
Bérangère Boggio Independent Director
Bernard Kubbinga Director
Sector and Competitors
1st jan.Capitalization (M$)
SPINEWAY SA-18.67%3
MEDTRONIC PLC5.12%159 813
BAXTER INTERNATIONAL INC.8.26%46 221
HOYA CORPORATION4.97%37 703
ZIMMER BIOMET HOLDINGS-1.10%30 450
TERUMO CORPORATION3.72%27 063